Navigation Links
Gentris Corporation Partners with BioFortis, Announces New Vice President of Information Technology
Date:9/25/2013

MORRISVILLE, N.C., Sept. 25, 2013 /PRNewswire/ -- Gentris® Corporation (www.gentris.com), a global leader in pharmacogenomics and biorepository solutions, announced today that it has partnered with BioFortis to integrate its Labmatrix™ and Qiagram™ software into Gentris' laboratory operations. The Labmatrix™ and Qiagram™ software will provide an advanced platform for clients to view and manage samples housed in the Gentris biorepository, while simultaneously enhancing their ability to collect, harmonize, and integrate multiple data sources, e.g., clinical, molecular, patient, and biospecimen data. In addition, Gentris has recently hired John Doyle as Vice President of Information Technology to lead the implementation of BioFortis' solution. John brings with him over 25 years of experience at IBM, which he will leverage as he continues to grow and enhance Gentris' IT infrastructure.

(Logo: http://photos.prnewswire.com/prnh/20130916/CL80771LOGO)

BioFortis is a leading provider of web-based, enterprise-class, scientific intelligence solutions for clinical and translational research. Its Labmatrix™ and Qiagram™ software were created to integrate and query disparate data from multiple sources including biomarker, translational, clinical, and healthcare data sets. This highly flexible platform allows for the seamless aggregation and exchange of existing and new data sets, making it accessible to multiple stakeholders. By combining Labmatrix™ ability to facilitate more efficient and effective analysis of scientific data across an organization with Gentris' biobanking and genomic biomarker services, the two companies can help pharmaceutical and biotechnology sponsors accelerate translational research and advance the application of personalized medicine to improve patient care.

"We are extremely excited to have the opportunity to partner with a cutting-edge company like BioFortis," said John Doyle, Gentris Vice President, Information Technology. "One of the biggest hurdles for large pharmaceutical and biotechnology companies looking to capitalize on the potential of genomic biomarkers and personalized medicine is the inability to integrate distributed data sources, legacy systems, and different data-types. Together, Gentris and BioFortis can help clients better manage their clinical samples, seamlessly incorporate genomic testing, and most importantly, effectively and efficiently convert the tremendous amount of data they collect into actionable information."

John Doyle was hired as Vice President of Information Technology to drive the evolution of Gentris' IT infrastructure and lead the implementation of the Labmatrix™ and Qiagram™ software. John served as a programmer at IBM for 14 years assuming increasing responsibilities before transitioning into a software engineer role in 2001. He has extensive experience in all phases of the software development lifecycle including the design, configuration, deployment, and implementation of Java Enterprise systems. Under John's leadership, Gentris will continue to improve its IT systems and infrastructure in order to meet client demands and expand the company's informatics and bioinformatics capabilities. John received his Bachelor's of Science degree in Computer and Information Science from Bloomsburg University of Pennsylvania. He received his Master's of Science degree in Computer and Information Science from Villanova University.

Related Links: www.gentris.com, www.biofortis.com

About Gentris Corporation:
Founded in 2001, Gentris is located in Research Triangle Park, NC, where it provides pharmacogenomics and biorepository support for all phases of clinical studies and genomic biomarker programs. The Company works with academic and industry leaders to translate innovations in pharmacogenomics into safer, more effective medicines, which can lead to accelerated drug development and improvement in patient care globally. In the past year, Gentris has significantly expanded its facility and onsite biorepository to meet the increased needs of biopharma clients, while maintaining a preeminent quality system.

About BioFortis:
BioFortis, Inc. is a software company focused on addressing the challenges in today's data-intensive environments. Founded in 2002 by transfer of the Labmatrix™ technology from The Johns Hopkins University School of Medicine, the company has since become a leading provider of information management solutions for the translational life science research community. Labmatrix has grown to support numerous organizations in a variety of application areas including translational clinical and genetic research, personalized medicine and biomarker studies, as well as biobanking.


'/>"/>
SOURCE Gentris Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Bluechiip Signs Strategic Partnership with Gentris Corporation
2. Harwood Feffer LLP Announces Investigation of Verenium Corporation
3. Celladon Corporation Announces Appointment of Gregg Alton and Graham Cooper to its Board of Directors
4. China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2014
5. China Cord Blood Corporation to Report First Quarter of Fiscal 2014 Financial Results
6. Celladon Corporation Announces Pre-clinical Study Demonstrating Inhalable MYDICAR Reverses Pulmonary Arterial Hypertension (PAH)
7. Verenium Corporation To Announce Second Quarter 2013 Financial Results
8. United Therapeutics Corporation Reports Second Quarter 2013 Financial Results
9. Techne Corporation Announces Acquisition Completion
10. United Therapeutics Corporation to Announce Second Quarter 2013 Financial Results Before Market Open on Thursday, July 25, 2013
11. Hurel Corporation Launches Cell-Based In Vitro Testing Product Suite, Milestone in Movement Away from Use of Live Animals in Drug and Toxicity Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
(Date:6/22/2016)... DIEGO , June 22, 2016 ... that will allow them to produce up to ... from one lot within one week. These high-quality, ... time laboriously preparing cells and spend more time ... possible through a proprietary, high-volume manufacturing process that ...
Breaking Biology Technology:
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
Breaking Biology News(10 mins):